<DOC>
	<DOCNO>NCT01305980</DOCNO>
	<brief_summary>The purpose study determine efficacy SB injection Colorectal Cancer .</brief_summary>
	<brief_title>Evaluating Safety Efficacy SB Injection Patients With Advanced Metastatic Colorectal Cancer</brief_title>
	<detailed_description>All eligible patient receive SB injection therapy 6 cycle ( 14~21 day cycle ) . Efficacy evaluate every 3 cycle .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Age 18years Patients fail 1 cycle standard therapy advance metastatic stage measurable lesion Life expectancy &gt; /= 5 month Not available resectable surgery radiotherapy Patients adequate organ ( e.g . heart , kidney , liver ) bone marrow function , define 1 . Absolute neutrophil count &gt; /= 1.0 x 10^9/L , Platelet count &gt; /= 75 x 10^9/L 2 . Total bilirubin &lt; 2.0 mg/dL 3 . Aspartate Aminotransferase and/or Aspartate Aminotransferase &lt; 5 x Upper Limit Normal 4. creatinine &lt; 2 x Upper Limit Normal ECOG status 0 2 Female volunteer admit study must use reliable mean contraception must negative blood urine pregnancy test least 7days ago Patients legal representative sign informed consent form . Have inflammatory bowel disease Have severe diarrhea ileus Previous total colectomy Have ileostomy Known brain spinal cord metastases Patients receive chemotherapy within previous 4 week Patients receive radiotherapy relate tp colorectal cancer within 4weeks Patients participate clinical study within previous 4weeks Pregnancy lactation period Human Immunodeficiency Virus antibody ( + ) Have active infection serious concomitant systemic disorder incompatible study Clinically hypertension diabetes mellitus well control medication Clinically significant cardiac disease ( congestive heart failure , symptomatic coronary artery disease cardiac arrhythmia ) myocardial infarction Presence history malignancy colorectal cancer within 5years Have severe Neurologic psychological disorder Patients history allergy investigational drug ( SB injection ) Obvious cognitive physical impairment would prevent participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>